Alzchem invests €120m in creatine capacity amidst 300% demand surge
German manufacturer Alzchem is committing €120 million to new production facilities to address a critical creatine supply deficit, driven by a 300% demand increase over two years.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Trostberg, Germany — Alzchem Group, the primary non-Asian producer of creatine monohydrate, is investing €120 million into new production facilities in Germany to mitigate severe supply shortages. The move follows an unprecedented 300% surge in global creatine demand over the past two years, significantly outpacing existing manufacturing capacity. Robert Alber, Vice President of Human Nutrition at Alzchem, confirmed that new market assessments underscore the exponential growth, driven by expanded applications beyond traditional sports nutrition, including women's health, cognitive function, and healthy ageing.
The investment aims to alleviate immediate supply pressures, with the new facility expected to commence operations in late 2027. Until then, brand owners should anticipate continued supply constraints for high-purity creatine, particularly Creapure. Alzchem's unique position as the sole Western manufacturer of creatine monohydrate, guaranteeing a minimum of 99.9% purity, makes its supply critical for brands prioritising quality and avoiding cross-contamination concerns.
Concurrently, the Singapore government has allocated SGD$350 million (US$273 million) to its 'Grand Challenge on Maximising Healthy and Successful Longevity'. This initiative, announced by Minister for Health Ong Ye Kung, targets research in brain health, physical function, and socio-environmental innovations. This substantial funding injection is part of Singapore's Research, Innovation and Enterprise 2030 (RIE 2030) framework, signalling a strategic national focus on active ageing and fostering a robust ecosystem for longevity-focused product development.
What this means for United Kingdom
UK brand owners relying on high-purity creatine will face prolonged lead times and increased commodity pricing until Alzchem's new capacity comes online in late 2027. Procurement teams should explore multi-source strategies now, accepting that consistency might vary. The Singaporean longevity investment signals a future market shift; UK brands can pre-empt this by directing R&D towards clinically validated ingredients for brain health and physical function. Early investment in these areas, backed by robust science, will position UK brands competitively as consumer demand for active ageing solutions solidifies, potentially creating new premium segments by 2028.
With demand for creatine already tripling, Alzchem's current limitations mean they cannot fully satisfy new inquiries, impacting market expansion for brands looking to leverage creatine's growing mainstream appeal. The confluence of these factors suggests a tightening market for established ingredients and a burgeoning research-driven segment for novel longevity-focused components.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.